نتایج جستجو برای: alk kinase

تعداد نتایج: 231548  

Journal: :Blood 2007
Vasiliki Leventaki Elias Drakos L Jeffrey Medeiros Megan S Lim Kojo S Elenitoba-Johnson Francois X Claret George Z Rassidakis

Anaplastic large-cell lymphoma (ALCL) frequently carries the t(2;5)(p23;q35), resulting in aberrant expression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). We show that in 293T and Jurkat cells, forced expression of active NPM-ALK, but not kinase-dead mutant NPM-ALK (210K>R), induced JNK and cJun phosphorylation, and this was linked to a dramatic increase in AP-1 transcriptional activ...

2013
Yi-Cheng Wu Il-Chi Chang Chi-Liang Wang Tai-Di Chen Ya-Ting Chen Hui-Ping Liu Yen Chu Yu-Ting Chiu Tzu-Hua Wu Li-Hui Chou Yi-Rong Chen Shiu-Feng Huang

BACKGROUND Recently Echinoderm microtubule-associated protein-like 4- anaplastic lymphoma kinase (EML4-ALK) fusion gene has become an important biomarker for ALK tyrosine kinase inhibitor (crizotinib) treatment in NSCLC. However, the best detection method and the significance of EML4-ALK variant types remain uncertain. METHODS Reverse transcriptase-polymerase chain reaction (RT-PCR), fluoresc...

Journal: :Drug discoveries & therapeutics 2015
Soichiro Sawamura Ikko Kajihara Asako Ichihara Satoshi Fukushima Masatoshi Jinnin Emi Yamaguchi Hirotsugu Kohrogi Hironobu Ihn

Crizotinib is an oral small-molecule anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor for the treatment of ALK-positive non-small-cell lung cancer (NSCLC). A 63-year old woman with postoperative relapsed ALK-positive NSCLC was treated with crizotinib. Erythema multiforme (EM) occurred one week after initiation of crizotinib therapy. Skin biopsy specimen showed compatible drug eruption...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013
Alice T Shaw Jeffrey A Engelman

In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers. ALK-positive cancers are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. Phase I and II studies of crizotinib in ALK-positive lung cancer demonstrated impressive activity and clinical benefit, leading to rapid US Foo...

Journal: :The Journal of molecular diagnostics : JMD 2003
N Scott Reading Stephen D Jenson Jeffrey K Smith Megan S Lim Kojo S J Elenitoba-Johnson

Anaplastic large-cell lymphoma (ALCL) is a subtype of aggressive non-Hodgkin’s lymphoma first described in 1985, and characterized by the expression of CD30/Ki-1 antigen. By current definition, ALCLs exhibit a T-cell or null phenotype and the majority of cases demonstrate expression of the anaplastic lymphoma kinase (ALK) protein. Most ALK-expressing ALCLs harbor the t(2;5)(p23; q35) chromosoma...

2009
Yu-Xin Cui Alan Kerby Fiona Kate Elizabeth McDuff Hongtao Ye Suzanne Dawn Turner

Anaplastic large cell lymphoma (ALCL) is characterized by the presence of the t(2;5)(p23;q35) generating the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion protein, a hyperactive kinase with transforming properties. Among these properties is the ability to regulate activity of the p53 tumor suppressor protein. In many human cancers, p53 is inactivated by mutation or other means, in s...

2011
Fiona Kate Elizabeth McDuff Suzanne Dawn Turner

Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase aberrantly expressed in a variety of tumor types, most notably in Anaplastic Large Cell Lymphoma (ALCL) where a chromosomal translocation generates the oncogenic fusion protein, Nucleophosmin-ALK (NPM-ALK). Whilst much is known regarding the mechanism of transformation by NPM-ALK, the existence of cellular defence pathways to preven...

2015
Jikui Guan Ganesh Umapathy Yasuo Yamazaki Georg Wolfstetter Patricia Mendoza Kathrin Pfeifer Ateequrrahman Mohammed Fredrik Hugosson Hongbing Zhang Amy W Hsu Robert Halenbeck Bengt Hallberg Ruth H Palmer

Aberrant activation of anaplastic lymphoma kinase (ALK) has been described in a range of human cancers, including non-small cell lung cancer and neuroblastoma (Hallberg and Palmer, 2013). Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we show that FAM150A and FAM150B are potent ligands for human ALK that bind to the ex...

2016
Patrizia Gasparini Michela Casanova Raffaella Villa Paola Collini Rita Alaggio Angelica Zin Paolo Bonvini Cristina R Antonescu Renata Boldrini Roberto Caserini Massimo Moro Giovanni Centonze Cristina Meazza Maura Massimino Luca Bergamaschi Roberto Luksch Stefano Chiaravalli Gianni Bisogno Nadia Zaffaroni MariaGrazia Daidone Gabriella Sozzi Andrea Ferrari

Rhabdomyosarcoma (RMS) is the most frequent soft tissue tumor in childhood and arises from immature mesenchymal cells committed to skeletal muscle differentiation. Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase aberrantly expressed in several cancers. Moreover, ALK full-length receptor protein has been observed in RMS, although its clinical and functional significance is yet con...

2015
K M Bone P Wang F Wu C Wu L Li J T Bacani S E Andrew R Lai

The vast majority of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ALCL) tumors express the characteristic oncogenic fusion protein NPM-ALK, which mediates tumorigenesis by exerting its constitutive tyrosine kinase activity on various substrates. We recently identified MSH2, a protein central to DNA mismatch repair (MMR), as a novel binding partner and phosphorylation ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید